AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93 $
arrow_upward
+0,96%(+0,53) 1D
13 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 մլրդ
Avg. vol.
1,98 մլն
Volume
10,00
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 մլն
No. of employees
622
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 մլրդ
Avg. vol.
1,98 մլն
Volume
10,00
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 մլն
No. of employees
622
News stories
From web sources and news partners
MarketWatch
·
1 ժամ առաջ
Stock Market Today: Dow, S&P 500 and Nasdaq are set to fall as investors await Nvidia results and Anthropic's IPO this week: live updates
Investing.com
·
1 ժամ առաջ
Morgan Stanley raises S&P 500 target on earnings growth, lower oil and AI adoption
The Motley Fool
·
2 ժամ առաջ
The S&P 500 Looks Cheaper Than It Has in Over 3 Years, but There’s a Catch
Billionaires.Africa
·
16 րոպե առաջ
American billionaire Elon Musk's SpaceX eyes S&P 500 entry through Tesla merger
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Ֆլորիդա, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websiteaxogeninc.com